All In Biotech

Drug Trial Radar · NCT03720470

Study Evaluating Efficacy and Safety of PF-04965842 and Dupilumab in Adult Subjects With Moderate to Severe Atopic Dermatitis on Background Topical Therapy

A PHASE 3 RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, PLACEBO-CONTROLLED, PARALLEL GROUP, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 AND DUPILUMAB IN COMPARISON WITH PLACEBO IN ADULT SUBJECTS ON BACKGROUND TOPICAL THERAPY, WITH MODERATE TO SEVERE ATOPIC DERMATITIS

Last checked: Nov 19, 2026Latest source record: Jan 19, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 838 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

838

Actual

Start

Oct 29, 2018

Primary completion

Dec 27, 2019

Study completion Mar 6, 2020

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Oct 25, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

B7451029 is a Phase 3 study to investigate PF-04965842 in adult patients who have moderate to severe atopic dermatitis and use background topical therapy. The efficacy of two dosage strengths of PF-04965842, 100 mg and 200 mg taken orally once daily will be evaluated relative to placebo over 12 weeks. The efficacy of the two dosage strengths of PF-04965842 will be compared with dupilumab in terms of pruritus relief at 2 weeks. The two dosage strengths of PF-04965842 and dupilumab 300 mg injected subcutaneously once every two weeks (with a loading dose of 600 mg injected on the first day) will also be evaluated relative to placebo over 16 weeks. The safety of the investigational products will be evaluated over the duration of the study. Subjects will use non-medicated emollient at least twice a day and medicated topical therapy such as corticosteroids, calcineurin inhibitors or PDE4 inhibitors, as per protocol guidance, to treat active lesions during the study. Subjects who are randomized to receive one of the two dosage strengths of PF-04965842 will also receive placebo injectable study drug every two weeks until Week 16 and then will continue on receiving only the oral study drug for 4 weeks. Subjects who are randomized to receive dupilumab injections every two weeks will also receive oral placebo to be taken once daily until Week 16 and will then continue to receive only the oral placebo for 4 weeks. Subjects who are randomized to the placebo arms, will receive both daily oral placebo and injectable placebo every two weeks until Week 16, after which they will receive either 100 mg or 200 mg of PF-04965842 taken orally once daily for 4 weeks, dependent upon which arm they have been allocated to. Eligible subjects will have an option to enter a long-term extension study after completing 20 weeks of treatment.

Conditions

  • Dermatitis
  • Dermatitis, Atopic
  • Eczema
  • Skin Diseases
  • Skin Diseases, Genetic
  • Genetic Diseases, Inborn
  • Skin Diseases, Eczematous
  • Hypersensitivity
  • Hypersensitivity, Immediate
  • Immune System Diseases

Interventions

  • PF-04965842 100 mgDrug

    PF-04965842 100 mg, administered as two tablets to be taken orally once daily as follows: 1. In the arm "PF-04965842 100 mg + Injectable Placebo followed by PF-04965842 100 mg," PF-04965842 100 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20; 2. In the arm "Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842" subjects take PF-04965842 100 mg from Week 16 to Week 20.

  • PF-04965842 200 mgDrug

    PF-04965842 200 mg, administered as two tablets to be taken orally once daily as follows: 1. In the arm "PF-04965842 200 mg + Injectable Placebo followed by PF-04965842 100 mg," PF-04965842 200 mg is taken together with Injectable Placebo from Day 1 until Week 16, then by itself from Week 16 to Week 20; 2. In the arm "Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842" subjects take PF-04965842 200 mg from Week 16 to Week 20.

  • DupilumabDrug

    Two subcutaneous injections of Dupilumab 300 mg as a loading dose administered on Day 1 (for a total of 600 mg) followed by one injection once every two weeks (q2w) until Week 16.

  • Oral PlaceboDrug

    Oral placebo (for PF-04965842) administered as two tablets to be taken orally once daily as follows: 1. In the arm "Dupilumab Injection + Oral Placebo followed by Oral Placebo," the Oral Placebo is taken together with Dupilumab from Day 1 until Week 16, then by itself to Week 20; 2. In the arms "Oral Placebo + Injectable Placebo followed by 100 mg PF-04965842" and "Oral Placebo + Injectable Placebo followed by 200 mg PF-04965842," subjects, take Oral Placebo from Day 1 until Week 16.

  • Injectable PlaceboDrug

    Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving Investigator's Global Assessment (IGA) Response of Clear (0) or Almost Clear (1) and a Reduction of Greater Than or Equal to (>=) 2 Points From Baseline at Week 12Time frame: Baseline (the last measurement prior to first dosing on Day 1), Week 12
  2. Percentage of Participants Achieving Eczema Area and Severity Index (EASI) Response >=75 Percent (%) Improvement From Baseline at Week 12Time frame: Baseline, Week 12

Locations

216 sites in 18 countries. Site status is shown where the registry gives one.

  • Clinical Research Center of Alabama, LLC

    Birmingham, Alabama

  • The University Of Alabama At Birmingham

    Birmingham, Alabama

  • Marvel Research, LLC

    Huntington Beach, California

  • Alliance Research Centers

    Laguna Hills, California

  • Allergy & Asthma Care Center of Southern California

    Long Beach, California

  • Allergy & Asthma Associates of Southern California dba Southern California Research

    Mission Viejo, California

  • Dermatology Specialists, Inc.

    Murrieta, California

  • MedDerm Associates

    San Diego, California

  • Clinical Science Institute

    Santa Monica, California

  • Synexus Clinical Research US, Inc.

    Santa Rosa, California

  • IMMUNOe Research Centers

    Centennial, Colorado

  • Renaissance Research and Medical Group, Inc

    Cape Coral, Florida

  • C & R Research Services USA, Inc

    Coral Gables, Florida

  • Florida Academic Centers Research and Education, LLC

    Coral Gables, Florida

  • Moonshine Research Center, Inc.

    Doral, Florida

  • Solutions Through Advanced Research, Inc.

    Jacksonville, Florida

  • Olympian Clinical Research

    Largo, Florida

  • Savin Medical Group LLC

    Miami, Florida

  • Wellness Clinical Research, LLC

    Miami Lakes, Florida

  • ForCare Clinical Research

    Tampa, Florida

  • Research Institute of Southeast, LLC

    West Palm Beach, Florida

  • Research Institute of the Southeast, LLC

    West Palm Beach, Florida

  • Columbus Regional Research Institute

    Columbus, Georgia

  • Idaho Allergy and Research

    Eagle, Idaho

  • ASR, LLC

    Nampa, Idaho

  • Great Lakes Clinical Trials

    Chicago, Illinois

  • Midwest Allergy Sinus Asthma, SC

    Normal, Illinois

  • NorthShore University HealthSystem

    Skokie, Illinois

  • Southern Illinois University School of Medicine

    Springfield, Illinois

  • Dundee Dermatology

    West Dundee, Illinois

  • The Indiana Clinical Trials Center

    Plainfield, Indiana

  • Forefront Dermatology, S.C.

    Louisville, Kentucky

  • Meridian Clinical Research, LLC

    Baton Rouge, Louisiana

  • Clinical Research Institute, Inc.

    Minneapolis, Minnesota

  • Skin Laser and Surgery Specialists of NY and NJ

    Hackensack, New Jersey

  • Forest Hills Dermatology Group

    Kew Gardens, New York

  • Juva Skin and Laser Center

    New York, New York

  • TrialSpark, Inc (Russell Cohen)

    Oceanside, New York

  • Cary Dermatology Center, PA

    Cary, North Carolina

  • PMG Research of Raleigh, LLC d/b/a PMG Research of Cary

    Cary, North Carolina

Showing 40 of 216 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.